SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is surging following a positive clinical update that highlights an annual recurrence rate of less than 1% in the open-label arm of its Phase III trial, fueling community optimism about the company's competitive position. Investors are actively discussing the trial's statistically significant results compared to industry standards, the high level of insider ownership, and growing anticipation for upcoming abstract presentations.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is currently trading in a tight consolidation range as investors weigh record-breaking revenue and strong AI infrastructure demand against margin compression concerns and lingering sentiment around historical accounting reports. The community is actively debating the company's long-term value, with many hopeful that upcoming industry conferences and strategic NVIDIA ecosystem partnerships will finally catalyze a breakout from the stock's multi-month sideways trend.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

Ripple's XRP is trending as traders closely monitor its recent price action and resistance levels, with many community members debating whether the current move is a sustainable breakout or another manipulation trap. The conversation is heavily polarized between long-term holders citing institutional adoption and potential utility, and skeptics who remain wary of market volatility and its historical correlation with broader crypto movements.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging following a massive five-year, $27 billion AI infrastructure deal with Meta, which builds on a recent $2 billion equity investment from Nvidia. The community is heavily focused on the company's rapid hyperscaler expansion, debating the implications of this contract for future revenue and whether the stock's valuation is poised for a sustained breakout or a potential pullback.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

The XRP community is currently polarized as the Bitwise XRP ETF launch drives intense debate over its role in institutional adoption versus speculative price manipulation. Traders remain divided between those aggressively buying into the current price volatility and others expressing deep skepticism about the asset's long-term utility and historical price action.

Coda Octopus Group, Inc. engages in the developing, manufacturing, and marketing of subsea products. The firm operates through the following segments: Marine Technology Business (Products), Acoustics Sensors and Materials Business (PAL), and Defense Engineering Services Business. The Marine Technology Business segment develops solutions for subsea and underwater markets. The Acoustics Sensors and Materials Business segment engages in the provision of a comprehensive range of products and solutions, with a primary focus on medical imaging and Non-Destructive Testing. The Defense Engineering Services Business segment engages in defense contractors and designs, engineers, manufactures and supplies proprietary sub-assemblies for incorporation into broader mission critical defense systems. It also operates through the Americas, Europe, Australia or Asia, and Middle East or Africa geographical segments. The company was founded in 1994 and is headquartered in Orlando, FL.

Coda Octopus Group Inc.

Coda Octopus Group is gaining traction as investors focus on its proprietary real-time 3D sonar technology, which is increasingly critical for subsea infrastructure, defense, and maritime security. The community is actively discussing the stock's multi-bagger potential, high institutional interest, and the significant demand for its specialized equipment in global underwater operations.

Citi Trends, Inc. engages in the retail of urban fashion apparel, accessories, and home trends. It offers products under its Citi Steps and Red Ape brands. The company was founded in 1946 and is headquartered in Savannah, GA.

Citi Trends Inc

Citi Trends is currently trending as investors monitor its strategic turnaround plan, which includes store expansion and inventory management, alongside a raised fiscal outlook that has drawn significant attention from traders. The community is actively debating the company's long-term operational consistency and its ability to navigate current consumer spending headwinds.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is drawing significant investor attention due to a surge in trading volume and speculation regarding a potential short squeeze, fueled by its pivot toward stablecoin settlement and institutional infrastructure. The community is actively discussing recent corporate developments, including share dilution, and is keenly anticipating an upcoming Investor Day that many hope will clarify the company's long-term growth strategy.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is facing significant operational headwinds as a prolonged government shutdown triggers mandatory flight capacity cuts and widespread cancellations, putting pressure on industry profit guidance. Despite these challenges, market sentiment remains cautiously optimistic as investors monitor the impact of rising fuel costs against the backdrop of robust travel demand and resilient corporate booking trends.

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals is capturing investor attention following consistently positive clinical data from its RESOLVE trial for EP-104GI in eosinophilic esophagitis, which validates the potential of its DiffuSphere delivery technology. The community is actively discussing the company's progress toward Phase 2b development and its growing pipeline, while analysts remain focused on the stock's long-term commercial potential and upcoming milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>One investor on Stocktwits said that the stock needs a new announcement to go higher.&nbsp;</li><li>Earlier in the month, the company was approved for uplisting to the New York Stock Exchange from the NYSE American.&nbsp;</li><li>The company was also awarded $27 Million by the Department of War (DOW) under Title III of the Defense Production Act to enhance, innovate, and expand domestic extraction.&nbsp;</li></ul>United States Antimony Corp. (UAMY)&nbsp;garnered retail interest on Monday as the ongoing war in Iran, and&nbsp;its recent uplisting to the New York Stock Exchange (NYSE)&nbsp;fueled investor optimism.&nbsp;On Stocktwits, retail sentiment jumped from ‘bullish to ‘extremely bullish’ territory over the past 24 hours.&nbsp;Meanwhile, message volume trended in the ‘high’ territory, with messages jumping 30% in the past day, according to Stocktwits data from Monday morning.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>Retail investors see&nbsp;a 350% upside&nbsp;to UAMY shares&nbsp;as many see the Iran&nbsp;war continuing, which could potentially lead to shortage of ammunition for the U.S.&nbsp;A retail investor on Stocktwits said that they will hold the stock till $50 and further opined that “the U.S. imports roughly 82% of its antimony, with China accounting for roughly 63%. China has previously restricted antimony exports to the U.S.”<stembedurl>https://stocktwits.com/Russiancolusion/message/647665883</stembedurl>Another investor said that the stock needs&nbsp;fresh news to go higher.&nbsp;<stembedurl>https://stocktwits.com/GO_DAWGS/message/647667560</stembedurl>Another user said that buyers remain aggressive on UAMY stock.&nbsp;<stembedurl>https://stocktwits.com/topstockalerts/message/647669921</stembedurl><h2 class="st-heading-2">Uplisting And Military Award</h2>Earlier in the month, the company was approved for uplisting to the New York Stock Exchange from the NYSE American.&nbsp;The uplisting to the NYSE marks a further advancement in the UAMY’s ongoing goal to continue enhancing its institutional and retail shareholder base by providing a new market maker specialist and enhanced trading characteristics on the NYSE.&nbsp;Earlier this month, the company was awarded $27&nbsp;million by the Department of War (DOW) under Title III of the Defense Production Act to enhance, innovate, and expand domestic extraction, processing, and refinement of critical materials.The award was approved last year but was delayed due to a government shutdown. DOW's $27 million investment in UAMY will fund modernization and expand the company's capacity located in Montana to refine and produce antimony necessary for flame retardants, batteries, munitions, and other defense applications, it further added.&nbsp;Shares in the company have risen 108% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the United States Antimony (US Antimony) logo is seen displayed on a smartphone screen

Why Do Retail Investors Believe UAMY Shares Have A 350% Upside Potential?

United States Antimony Corp. garnered retail interest on Monday as the ongoing war in Iran, and its recent uplisting to the New York Stock Exchange fueled investor optimism. 

Equity

United States Antimony Corp. garnered retail interest on Monday as the ongoing war in Iran, and its recent uplisting to the New York Stock Exchange fueled investor optimism. 


<ul class="summary-bullets"><li>Sable’s onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill.</li><li>California Attorney General Rob Bonta had filed a lawsuit against the Trump Administration in January, challenging the PHMSA orders that “illegally assert” exclusive jurisdiction over two California onshore oil pipelines of Sable offshore.</li></ul>Sable Offshore shares rallied nearly 10% on Friday after White House invoked Defense Production Act aimed at bypassing California state regulations to allow oil production off the state coast in bid to ease global oil supply pressures created due to the ongoing Iran war.&nbsp;“Today’s order will strengthen America’s oil supply and restore a pipeline system vital to our national security and defense, ensuring that West Coast military installations have the reliable energy critical to military readiness”, Energy Secretary Chris Wright reportedly said. It was followed by an executive order by Donald Trump adjusting certain delegations under the U.S. Defense Production Act.&nbsp;Energy Secretary Chris Wright directed Sable Offshore Corp. to begin restoring operations for the Santa Ynez Unit and Santa Ynez Pipeline System in California, Bloomberg News report said.<h2 class="st-heading-2">Sable-California&nbsp;</h2>Sable’s onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill, when a corroded segment of one pipeline ruptured and released hundreds of thousands of gallons of oil near Santa Barbara.California Attorney General Rob Bonta in January had filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders that “illegally assert” exclusive jurisdiction over two California onshore oil pipelines of Sable offshore which are known as the Las Flores Pipelines or lines CA-324 and CA-325, and allow them to restart operations.&nbsp;<h2 class="st-heading-2">Iran’s War Hitting Oil Supplies</h2>The efforts come at a time when the U.S.-Israel war with Iran has disrupted global supply of oil and other key energy products due to the blockade of Strait of Hormuz by Iran.The International Energy Agency this week announced it will release 400 million barrels of oil from their emergency reserves to help address disruptions in oil markets caused by the war in the Middle East.&nbsp;Retail sentiment around SOC trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in SOC have jumped 72% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trump Clears Path For Sable To Restart California Operations Amid Ongoing Iran War

 Energy Secretary Chris Wright directed Sable Offshore Corp. to begin restoring operations for the Santa Ynez Unit and Santa Ynez Pipeline System in California, Bloomberg News report said.

<ul class="summary-bullets"><li>The company swung to profit in Q4 and reported earnings per share of $0.05 versus year-ago loss per share of $0.22.</li><li>Adjusted operating expenses for the fourth quarter of 2025 were $6.5 million compared to $11.9 million for the fourth quarter of 2024.</li><li>On Stocktwits, retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;</li></ul>DigiMarc (DMRC) shares rallied 7% during extended hours of trading after it reported a&nbsp;higher-than-expected&nbsp;fourth-quarter (Q4) revenue on Wednesday.&nbsp;DMRC’s total revenue for Q4 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024. Analysts on average expected $8.2 million in revenue, as per data from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>DigiMarc’s subscription revenue for Q4 2025 came at $5.3 million compared to $5.0 million for the fourth quarter of 2024. The increase reflects $1.4 million of patent license fees earned during the quarter and higher subscription revenue from new and existing commercial contracts, partially offset by a $1.4 million decrease relating to the expiration of two previously disclosed commercial contracts in 2025,&nbsp;the company said.The company's adjusted net income for Q4 2025 was $1.0 million or $0.05 per diluted share compared to adjusted net loss of $4.6 million or $0.22 per diluted share for the fourth quarter of 2024.“Digimarc is capitalizing on the convergence of key trends driving increased demand for our solutions, positioning ourselves to benefit from - not be the casualty of - the relentless advance of AI," said Riley McCormack, Digimarc CEO. "In Q4 2025, we achieved both positive non-GAAP net income and positive free cash flow. Looking ahead to 2026, we expect to generate significant ARR growth."<h2 class="st-heading-2">Expenses Come Down</h2>Operating expenses for the quarter were $10.0 million, compared to $14.4 million for Q4 2024.&nbsp;The decrease was led by lower cash compensation costs of $4.4 million, largely due to lower headcount, and lower professional services costs of $0.6 million, partially offset by higher stock compensation costs of $0.7 million.&nbsp;Adjusted operating expenses for the quarter were $6.5 million compared to $11.9 million for Q4 2024.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 9.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, retail sentiment around DMRC stock trended in ‘extremely bullish’ territory amid ‘high’ message volume. 

DigiMarc Stock Rallies After Hours On Q4 Revenue Beat

DMRC’s total revenue for the fourth quarter of 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024.

<ul class="summary-bullets"><li>Northland also lowered the firm's price target on Webull to $14 from $18 and kept an ‘Outperform’ rating on the shares.</li><li>Northland cited lower peer multiples for the firm's lowered target.&nbsp;</li><li>The company on Wednesday posted net income per ordinary share of $0.01, below Wall Street estimates of $0.05 per share as per data from Fiscal.ai.</li></ul>Webull shares continued their decline on Thursday, falling more than 6%&nbsp;on the heels of fourth-quarter (Q4) earnings that fell short of analyst expectations. The shares also attracted price target&nbsp;cuts from several analysts.&nbsp;Rosenblatt lowered the firm's price target on Webull to $12 from $15 and kept a ‘Buy’ rating on the shares, per TheFly.Northland also lowered the firm's price target on Webull to $14 from $18 and kept an ‘Outperform’ rating on the shares.&nbsp;<h2 class="st-heading-2">Street Rationale</h2>Rosenblatt said Webull's Q4 results showed a strong top-line beat and record account growth, though elevated marketing spend offset some upside, resulting in over $20 million in adjusted core profit. Progress in crypto, prediction markets, and international initiatives positions the company well for 2026 and supports above-consensus growth expectations, the firm said in a research note.&nbsp;Meanwhile, Northland said that Webull reported "nice growth and higher marketing spend" in Q4, however citing lower peer multiples for the firm's lowered target, as per TheFly.&nbsp;<h2 class="st-heading-2">Q4 Report</h2>Webull posted its Q4 results on Wednesday,&nbsp;reporting a total revenue jump of 50% year-over-year to $165.2 million compared to a street expectation of $161.3 million as per data from Fiscal.ai. It was helped by a 56% rise in trading-related revenue year-over-year,&nbsp;the company said.&nbsp;The company posted net income per ordinary share of $0.01, below Wall Street estimates of $0.05 per share, as per data from Fiscal.ai.Webull launched corporate bond trading for U.S. customers in Q4, building on its previous rollout of U.S. government bond trading, which has enabled further user portfolio diversification. Webull’s customer assets totaled $24.6 billion, an all-time high, representing 81% year-over-year growth, driven by market recovery and strong net deposits, which grew 225% year-over-year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BULL stock trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.Shares in the company have fallen nearly 28% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of Webull Corporation.

Webull Stock Continues Decline After Q4 Earnings Miss – What Does The Street Think?

Rosenblatt lowered the firm's price target on Webull to $12 from $15 and kept a ‘Buy’ rating on the shares, per TheFly.

<ul class="summary-bullets"><li>The company reported a total revenue jump of 50% year-over-year to $165.2 million.&nbsp;</li><li>This was helped by a 56% rise year-over-year in trading-related revenue.&nbsp;</li><li>Webull’s customer assets totaled $24.6 billion, an all-time high, representing 81% year-over-year growth, driven by market recovery and strong net deposits.&nbsp;</li></ul>Webull shares fell in extended hours of trading on Wednesday after it posted a fourth-quarter (Q4) profit that missed analyst estimates.&nbsp;The company posted net income per ordinary share of $0.01, below Wall Street estimates of $0.05 per share as per data from Fiscal.ai.&nbsp;Adjusted net income decreased to $14.6 million for the quarter, compared to $15.0 million for the prior year comparative quarter.Shares in the company were down 2.3% at the time of writing.&nbsp;<h2 class="st-heading-2">Earnings Snapshot</h2>The company reported a total revenue jump of 50% year-over-year to $165.2 million. It was helped by a 56% rise in trading-related revenue year-over-year.Webull launched corporate bond trading for U.S. customers in Q4, building on its previous rollout of U.S. government bond trading, which has enabled further user portfolio diversification.It also entered into a partnership with Meritz Financial Group to offer South Korean investors access to U.S. equity markets.&nbsp;"We reported another quarter of strong financial performance, particularly in our equities and options businesses, which contributed to a significant full-year revenue increase," said H.C. Wang, Chief Financial Officer of Webull. "We're seeing robust returns on our strategic investment in marketing, innovation and addressable market expansion and are confident that we are positioning Webull to deliver lasting shareholder value."<h2 class="st-heading-2">Customer Assets At All-Time High</h2>Webull’s customer assets totaled $24.6 billion, an all-time high, representing 81% year-over-year growth, driven by market recovery and strong net deposits, which grew 225% year-over-year.&nbsp;Its registered users increased 15% year-over-year to 26.8 million users and funded accounts increased to 5.0 million, representing 8% year-over-year growth.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BULL stock trended in ‘extremely bullish’&nbsp;territory amid ‘extremely high’ message volume.&nbsp;One bullish user praised the earnings and called the stock undervalued.&nbsp;<stembedurl>https://stocktwits.com/Prepthebull/message/646619291</stembedurl>Shares in the company have fallen nearly 25% year-to-date.&nbsp;

In this photo illustration, the Webull Corporation logo is seen displayed on a smartphone screen. 

Webull Stock Falls As Q4 Profit Miss Disappoints Traders

The company posted net income per ordinary share of $0.01 that was below Wall Street estimates of $0.05 per share as per data from Fiscal.ai. 

<ul class="summary-bullets"><li>U.S. President Donald Trump on Monday said that while the U.S. has projected a timeline of four to five weeks for the Iran mission, the country has the capability to extend it far longer.&nbsp;</li><li>In other news, Red Cat on Monday announced that Allen Control Systems (ACS), has joined the Red Cat Futures Initiative.</li><li>ACS will collaborate with Red Cat to evaluate integration opportunities between its Bullfrog autonomous counter-drone system and Red Cat’s secure ISR platforms.&nbsp;</li></ul>Red Cat Holdings stock&nbsp;caught investors’ attention on Monday after the U.S. and Israel launched coordinated strikes on Iran over the weekend,&nbsp;boosting demand for defense stocks.&nbsp;Red Cat Holding&nbsp;Red Cat Holdings Inc. (<a href="https://stocktwits.com/symbol/RCAT">RCAT</a>) stock surged nearly 17% at the time of writing.&nbsp;<h2 class="st-heading-2">Spike In Defense Stocks</h2>The U.S. and Israel’s attack on Iran&nbsp;over the weekend,&nbsp;and retaliatory strikes by Iran in the&nbsp;Gulf region has put defense-related stocks in focus, with several rallying&nbsp;in anticipation that the war&nbsp;is expected to last weeks.&nbsp;U.S. President Donald Trump on Monday said that while the U.S. has projected a timeline of four to five weeks for the Iran mission, the country has the capability to extend it far longer.&nbsp;Red Cat is a drone technology company that integrates robotic hardware and software for military, government, and commercial operations.<h2 class="st-heading-2">Other News</h2>Red Cat on Monday announced that Allen Control Systems (ACS), has joined the Red Cat Futures Initiative, the company’s industry-wide consortium accelerating advanced autonomous systems for modern warfare.ACS will collaborate with Red Cat to evaluate integration opportunities between its Bullfrog autonomous counter-drone system and Red Cat’s secure (Intelligence, surveillance, and reconnaissance) ISR platforms, and command and control architecture.“U.S. and allied nations are seeking cost-effective and scalable counter-drone systems to provide a new layer of protection on the move and at the edge,” said Mike Wior, co-founder and CEO of ACS.&nbsp;“Partnering with Red Cat and joining the Futures Initiative allows us to integrate our fully autonomous precision weapons station into a proven unmanned platform, advancing these systems beyond basic requirements and enabling them to execute more advanced and complex missions for U.S. military forces and their allies,” Wior added.&nbsp;&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RCAT&nbsp;shares trended in&nbsp;the ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;One bullish user said that predicted $20 as the price target for the current week.&nbsp;<stembedurl>https://stocktwits.com/JMJTrading/message/646341982</stembedurl>Shares in the company have jumped 117% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Red Cat Holdings logo is seen displayed on a smartphone screen. 

Red Cat Stock Surges On US-Israel-Iran War

The U.S. and Israel’s attack on Iran over the weekend, and retaliatory strikes by Iran in the Gulf region has put defense-related stocks in focus, with several rallying in anticipation that the war is expected to last weeks. 

<ul class="summary-bullets"><li>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million and 25% YoY for the full year to $271 million.</li><li>LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.</li><li>Overall, LUPKYNIS sales accounted for about 96% of the company’s total revenue in Q4 and for the full year 2025.</li></ul>Aurinia Pharmaceuticals Inc. (AUPH) shares gained nearly 4% in Thursday’s pre-market trade after the company posted a fourth-quarter (Q4) earnings and revenue beat.Aurinia reported adjusted earnings per share (EPS) of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.However, the company’s 2026 revenue guidance fell short of Wall Street expectations. Aurinia guided for revenue in the range of $315 million and $325 million during the year, but the consensus estimate stood at $326.8 million.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels. The stock was among the top three trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Active Lupus Nephritis Therapy Sales Gain Momentum</h2>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million. For the full year, LUPKYNIS sales stood at $271 million, rising 25% YoY.LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.Overall, LUPKYNIS sales contributed to about 96% of the company’s total revenue in Q4 as well as the full year 2025.Aurinia also stated that the full-year revenue includes a $10 million milestone payment received by the company following the approval of LUPKYNIS by regulators in Japan.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user called Aurinia’s earnings and cash position “solid.”<stembedurl>https://stocktwits.com/VSTN/message/645950955</stembedurl>Another user called Aurinia’s numbers “excellent,” saying they’re excited for the company's long-term shareholders.<stembedurl>https://stocktwits.com/Ballerdad1/message/645950749</stembedurl><a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down 10% year-to-date, but up 80% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/celh-stock-soaring-today-celsius-q4-earnings-beat/cZTG9gDRIb8">CELH Stock Is Soaring Pre-Market Today — What Is Driving The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

<ul class="summary-bullets"><li>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.</li><li>The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index at week 12.</li><li>Evommune said EVO301 showed a favorable safety profile with no serious adverse events reported.</li></ul>Evommune Inc. (EVMN) shares nearly doubled in value in Tuesday’s pre-market trade before paring some of the gains to hover 50% higher in the opening trade after the company reported positive results from its atopic dermatitis trial.Evommune stated that its atopic dermatitis treatment, EVO301, met its primary endpoint at week 12 during the&nbsp;mid-stage trial. The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/EVMN">Evommune</a> trended in the ‘neutral’ territory at the time of writing. The EVMN stock was among the top five trending tickers on the platform.<h2 class="st-heading-2">Evommune Details Results Of The Trial</h2>Evommune stated that it designed the Phase 2a trial to evaluate the safety and efficacy of an intravenous 5 milligram per kilogram dose of EVO301 over 12 weeks.“These data support our plans to move EVO301 into a Phase 2b dose-ranging trial where we can optimize the dose and seek to further improve patient outcomes,” said Evommune President and CEO, Luis Peña.The company said it had 70 patients in the trial, and EVO301 achieved a 33% placebo-adjusted improvement in the Eczema Area and Severity Index (EASI) at week 12.Evommune said EVO301 showed a favorable safety profile, with no serious adverse events reported and no treatment-related discontinuations due to adverse events.Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, stated that EVO301’s ability to target the interleukin-18 (IL-18) mechanism and demonstrate clinically relevant activity could present patients with “real benefits.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One bullish user stated that there has been “only good news” with the Evommune stock so far.<stembedurl>https://stocktwits.com/swingingg/message/644564885</stembedurl>Another user stated that the IL-18, a known inflammatory pathway which plays a key role in various immune processes, is “working great” for dermatitis.<stembedurl>https://stocktwits.com/JanetBSmellin/message/644548490</stembedurl><a href="https://stocktwits.com/symbol/EVMN">EVMN stock</a> is up 45% year-to-date and 44% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/michael-saylor-bitcoin-volatility-bug-as-well-as-feature/cZbUI8AR4Yx">Michael Saylor Calls Bitcoin Volatility Both A Bug And A Feature, Touts It As ‘Digital Capital’: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?

The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.

Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?

<ul class="summary-bullets"><li>The first product on the list is Hydrelix, a Type 1 collagen powder that provides the bioactive components of collagen at the wound site.</li><li>The second product is NovaForm Wound Matrix, a bioglass- and collagen-based wound dressing intended for the management of partial- and full-thickness wounds.</li><li>Summit will also distribute G4Derm Plus, a flowable peptide matrix engineered for rapid, protected wound closure.</li></ul>MiMedx Group Inc. (MDXG) shares gained around 5% in Wednesday morning’s trade after the company entered into an exclusive distribution agreement with Summit Products Group for three of its 510(k) cleared products.According to the agreement, Summit will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MDXG">MiMedx</a> was in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">What Will Summit Distribute?</h2>The three products included in the agreement are intended to care for and enhance the closure of wounds.The first product in the list is Hydrelix, which is a Type 1 collagen powder that allows the bioactive components of collagen to be readily available at the wound site, facilitating a more direct and efficient therapeutic effect.The second product is NovaForm Wound Matrix, which is a bioglass and collagen-based wound dressing intended for use in the management of partial and full-thickness wounds. NovaForm can be used for pressure ulcers, venous ulcers, diabetic ulcers, and surgical wounds.&nbsp;The company says NovaForm is designed to maintain a moist environment that supports the body’s natural healing process while protecting the wound.Lastly, Summit will also distribute G4Derm Plus, a flowable peptide matrix engineered for rapid, protected wound closure, spurring tissue regrowth, and controlling bioburden. The company stated that G4Derm Plus mimics the human extracellular matrix (ECM) and acts as a barrier against bacteria.“These are innovative xenograft and synthetic products that strengthen our ability to serve the Surgical &amp; Wound markets,” said MiMedx’s Chief Commercial Officer, Kim Moller.<h2 class="st-heading-2">What Does MiMedx Do?</h2>MiMedx is a Marietta, Georgia-based company with a portfolio of surgical and wound care products designed to help clinicians manage chronic and other hard-to-heal wounds.In December 2025, the company entered into an exclusive agreement with Regen Lab USA LLC to distribute the latter’s RegenKit-Wound Gel in the U.S.<a href="https://stocktwits.com/symbol/MDXG">MDXG stock</a> is down 24% year-to-date and 40% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-openai-in-talks-to-customize-ai-models/cZbjTCvR4Zu">Amazon, OpenAI In Talks To Customize AI Models To Power E-commerce Giant's Products Such As Alexa: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products

According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.

VTWO
Vanguard Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VTWO News

VTWOVanguard Russell 2000 ETF